![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Boston_H_color%5B33632%5D_edited.png)
Live - Virtual
February 24, 2021
1:00 - 2:30 PM
Eastern Time
Program Description
Hepatocellular carcinoma (HCC) is a chronic inflammation due to HCV and HBV infection. Immunotherapy strategies with immune checkpoint inhibitors (ICIs) have shown promise in patients with HCC. Despite the initial enthusiasm, treatment benefit is appreciated in a modest proportion of patients (response rate to single-agent ~20%). Immune-related adverse events (irAEs) and economic impact are relevant concerns with ICI. It is essential to understand the mechanisms of action, either as monotherapy or in combination with multitargeted agents. This Live Virtual Broadcast and enduring webcast focuses on the latest developments in the immunotherapeutic approaches for HCC, the potential predictive biomarkers, and the rationale for combination therapies. This educational activity will familiarize the need for early diagnosis and treatment, new data to optimize the use of novel agents currently available.
Comentarios